# EDGAR Filing Document

**Accession Number:** 0000939767
**File Stem:** 0000939767-23-000033
**Filing Date:** 2023-3
**Character Count:** 8037
**Document Hash:** f6ae52d6c6cdfb49f02c471cae27b363
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000939767-23-000033.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0000939767-23-000033

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230320

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230320

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EXELIXIS, INC.
- **CENTRAL INDEX KEY:** 0000939767
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 043257395
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30235
- **FILM NUMBER:** 23744923

**BUSINESS ADDRESS:**
- **STREET 1:** 1851 HARBOR BAY PARKWAY
- **CITY:** ALAMEDA
- **STATE:** CA
- **ZIP:** 94502
- **BUSINESS PHONE:** 6508377000

**MAIL ADDRESS:**
- **STREET 1:** 1851 HARBOR BAY PARKWAY
- **CITY:** ALAMEDA
- **STATE:** CA
- **ZIP:** 94502

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXELIXIS INC
- **DATE OF NAME CHANGE:** 20000207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXELIXIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20000106

?xml version="1.0" ? exel-20230320

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**FORM**  | **8-K** |

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 20, 2023**

---

| |
|:---|
| ![exel-20230320_g1.jpg](exel-20230320_g1.jpg) |
| **EXELIXIS, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-30235** | **04-3257395** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**1851 Harbor Bay Parkway** 

**Alameda, California 94502**

(Address of principal executive offices) (Zip Code)

**(650) 837-7000** 

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of each class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| **Common Stock $.001 Par Value per Share** | **EXEL** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events.**

On March 20, 2023, Exelixis, Inc. announced that its Board of Directors authorized the repurchase of up to $550 million of its common stock before the end of 2023. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) &nbsp;&nbsp;&nbsp;&nbsp;Exhibits.**

---

| | | |
|:---|:---|:---|
| **Exhibit Number** | **Exhibit Description** | |
| 99.1 | <u>[Press Release](exhibit99120230320.htm)[issued](exhibit99120230320.htm)[March 20, 2023](exhibit99120230320.htm)</u> |  |
| 104 | Cover Page Interactive Data File | The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| | EXELIXIS, INC. |
| March 20, 2023 | /s/ JEFFREY J. HESSEKIEL |
| Date | **Jeffrey J. Hessekiel** |
| | Executive Vice President, General Counsel and Secretary |

---

## Exhibit 99.1

![image_0a.jpg](image_0a.jpg)

***Contacts:***

*Chris Senner*

*Chief Financial Officer*

*Exelixis, Inc.*

*650-837-7240*

*<u>csenner@exelixis.com</u>*

*Susan Hubbard*

*EVP, Public Affairs & Investor Relations*

*Exelixis, Inc.*

*650-837-8194*

*<u>shubbard@exelixis.com</u>*

**Exelixis Announces $550 Million Share Repurchase Program**

**ALAMEDA, Calif. – March 20, 2023 –** Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to $550 million of the company's common stock before the end of 2023.

The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis' common stock and general market conditions. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The program does not obligate Exelixis to acquire any particular amount of its common stock, and the share repurchase program may be modified, suspended or discontinued at any time without prior notice.

**<u>About Exelixis</u>**

**<u>Exelixis Forward-Looking Statements</u>**

This press release contains forward-looking statements, including, without limitation, statements related to Exelixis' intended share repurchases and repurchase timeframe; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties.

------

Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Exelixis' ability to effect repurchases under the share repurchase program due to changes in stock price, corporate or other economic or market conditions; the nature of other investment opportunities Exelixis may have from time to time; and other factors affecting Exelixis discussed under the caption "Risk Factors" in Exelixis' Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 7, 2023, and in Exelixis' future filings with the SEC. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

*Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.* 

\# \# \#

<br>